<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="brief-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">735357</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2021.735357</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cyclodextrins Exert a Ligand-like Current Inhibitory Effect on the K<sub>V</sub>1.3 Ion Channel Independent of Membrane Cholesterol Extraction</article-title>
<alt-title alt-title-type="left-running-head">Kovacs et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Cyclodextrins Directly Inhibit K<sub>V</sub>1.3 Current</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kovacs</surname>
<given-names>Tamas</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1041038/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sohajda</surname>
<given-names>Tamas</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Szente</surname>
<given-names>Lajos</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nagy</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/286086/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Panyi</surname>
<given-names>Gyorgy</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/33127/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Varga</surname>
<given-names>Zoltan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1234271/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zakany</surname>
<given-names>Florina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1194278/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Division of Biophysics, Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, <addr-line>Debrecen</addr-line>, <country>Hungary</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>CycloLab Cyclodextrin R and D Laboratory Ltd., <addr-line>Budapest</addr-line>, <country>Hungary</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/894000/overview">Laura Russo</ext-link>, Universit&#xe0; di Milano-Bicocca, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1327753/overview">Abhishek A. Kognole</ext-link>, University of Maryland, United&#x20;States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1458144/overview">Saurabh Gautam</ext-link>, ViraTherapeutics GmbH, Austria</p>
</fn>
<corresp id="c001">
<sup>&#x2a;</sup>Correspondence: Florina Zakany, <email>florina.zakany@med.unideb.hu</email>; Zoltan Varga, <email>veze@med.unideb.hu</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share last authorship.</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Glycoscience, a section of the journal Frontiers in Molecular Biosciences</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>8</volume>
<elocation-id>735357</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>07</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Kovacs, Sohajda, Szente, Nagy, Panyi, Varga and Zakany.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Kovacs, Sohajda, Szente, Nagy, Panyi, Varga and Zakany</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Cyclodextrins (CDs) are cyclic oligosaccharides capable of forming water-soluble complexes with a variety of otherwise poorly soluble molecules including cholesterol and different drugs. Consistently, CDs are widely used in research and clinical practice to deplete cholesterol from cellular membranes or to increase solubility and bioavailability of different pharmaceuticals at local concentrations in the millimolar range. Effects of CDs exerted on cellular functions are generally thought to originate from reductions in cholesterol levels. Potential direct, ligand-like CD effects are largely neglected in spite of several recent studies reporting direct interaction between CDs and proteins including AMP-activated protein kinase, &#x3b2;-amyloid peptides, and &#x3b1;-synuclein. In this study, by using patch-clamp technique, time-resolved quantitation of cholesterol levels and biophysical parameters and applying cholesterol-extracting and non-cholesterol-extracting CDs at 1 and 5&#xa0;mM concentrations, we provide evidence for a previously unexplored ligand-like, cholesterol-independent current inhibitory effect of CDs on K<sub>V</sub>1.3, a prototypical voltage-gated potassium channel with pathophysiological relevance in various autoimmune and neurodegenerative disorders. Our findings propose that potential direct CD effects on K<sub>V</sub> channels should be taken into consideration when interpreting functional consequences of CD treatments in both research and clinical practice. Furthermore, current-blocking effects of CDs on K<sub>V</sub> channels at therapeutically relevant concentrations might contribute to additional beneficial or adverse effects during their therapeutic applications.</p>
</abstract>
<kwd-group>
<kwd>cyclodextrin</kwd>
<kwd>cholesterol</kwd>
<kwd>membrane fluidity</kwd>
<kwd>membrane hydration</kwd>
<kwd>membrane lipid order</kwd>
<kwd>ligand-like interaction</kwd>
<kwd>K<sub>V</sub>1.3</kwd>
</kwd-group>
<contract-num rid="cn001">NTP-NFT&#xd6;-20-B-0115 Hungary grant EFOP-3.6.1-16-2016-00022</contract-num>
<contract-num rid="cn002">OTKA K132906 SNN139532 OTKA K119417 OTKA ANN133421 2019-2.1.11-T&#xc9;T-2019-00059 2020-1.1.2-PIACI-KFI-2020-00092</contract-num>
<contract-num rid="cn003">UNKP-19-3-III-DE-92 UNKP-21-4-II-DE-138 UNKP-21-4-II-DE-137</contract-num>
<contract-num rid="cn004">Hungary grant GINOP-2.3.2-15-2016-00044</contract-num>
<contract-sponsor id="cn001">Emberi Eroforr&#xe1;sok Miniszt&#xe9;riuma<named-content content-type="fundref-id">10.13039/501100005881</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Nemzeti Kutat&#xe1;si Fejleszt&#xe9;si &#xe9;s Innov&#xe1;ci&#xf3;s Hivatal<named-content content-type="fundref-id">10.13039/501100011019</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Ministry for Innovation and Technology<named-content content-type="fundref-id">10.13039/501100015498</named-content>
</contract-sponsor>
<contract-sponsor id="cn004">Ministry of Finance<named-content content-type="fundref-id">10.13039/501100005045</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Cyclodextrins (CDs) are cyclic oligosaccharides typically consisting of six (&#x3b1;CD), seven (&#x3b2;CD) or eight (&#x3b3;CD) alpha-D-glucopyranoside units (<xref ref-type="bibr" rid="B11">Davis and Brewster, 2004</xref>; <xref ref-type="bibr" rid="B47">Uekama, 2004</xref>). Their fundamental spatial structure exhibits a truncated cone-shaped conformation in which the degree of polymerization defines the size and the side-chain substitutions influence the hydrophobicity of their cavity. The most commonly applied CDs have a hydrophobic internal cavity and a hydrophilic outer surface, which creates a suitable milieu for making reversible water-soluble non-covalent complexes with a wide range of poorly soluble molecules including cholesterol and various drugs (<xref ref-type="bibr" rid="B11">Davis and Brewster, 2004</xref>; <xref ref-type="bibr" rid="B47">Uekama, 2004</xref>; <xref ref-type="bibr" rid="B30">Loftsson et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B43">Szente and Fenyvesi, 2017</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). Up to 100 medications currently available worldwide contain CDs as a main active agent to deplete cholesterol or as adjuvants in formulations to increase solubility and bioavailability of different pharmaceuticals.</p>
<p>In research, randomly-methylated-&#x3b2;-cyclodextrin (M&#x3b2;CD) is most widely used due to its highest efficiency among CD derivatives to extract cholesterol from the cell membrane (<xref ref-type="bibr" rid="B43">Szente and Fenyvesi, 2017</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). It is typically applied at 3&#x2013;5&#xa0;mM for 1&#xa0;h for membrane cholesterol depletion, while M&#x3b2;CD previously complexed with cholesterol potently elevates membrane cholesterol levels (<xref ref-type="bibr" rid="B55">Zidovetzki and Levitan, 2007</xref>; <xref ref-type="bibr" rid="B7">Bukiya et&#x20;al., 2021</xref>). In clinical practice and <italic>in vivo</italic> experiments, hydroxypropyl-&#x3b2;-cyclodextrin (HP&#x3b2;CD) is the most commonly employed CD to deplete cholesterol due to its better safety profile compared to M&#x3b2;CD (<xref ref-type="bibr" rid="B21">Irie and Uekama, 1997</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). When administered intravenously or intracerebroventricularly for the treatment of Niemann-Pick type C (NPC) disease, a rare lysosomal storage disorder characterized by cellular cholesterol accumulation, local HP&#x3b2;CD concentrations can reach concentrations in the millimolar range (<xref ref-type="bibr" rid="B32">Megias-Vericat et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B8">Carradori et&#x20;al., 2020</xref>).</p>
<p>Interestingly, hydroxypropyl-&#x3b3;-cyclodextrin (HP&#x3b3;CD), another biologically relevant CD derivative is also capable of decreasing cellular cholesterol levels despite its much lower affinity to form complexes with cholesterol <italic>in&#x20;vitro</italic> (<xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B49">Yamada et&#x20;al., 2021</xref>). This finding might draw attention to alternative CD-mediated cellular actions rather than solely focusing on cholesterol complexation. Per(3,6-anhydro)-CDs represent a scarcely known subfamily of CDs, which, as opposed to the original compounds, are characterized by an &#x201c;inverted&#x201d; structure with a hydrophilic interior and a hydrophobic outer surface (<xref ref-type="bibr" rid="B50">Yamamura et&#x20;al., 1993</xref>; <xref ref-type="bibr" rid="B2">Ashton et&#x20;al., 1996</xref>) (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). Anhydro CDs are modified not on hydroxyls but on the glucose core. The <sup>4</sup>C<sub>1</sub> chair conformation of the glucopyranose units is transformed into <sup>1</sup>C<sub>4</sub> form, resulting in this inverted unique structure. Therefore, these inverted cyclodextrin (iCD) derivatives are unlikely to form complexes with cholesterol, however, their cholesterol extracting efficacies have not been characterized&#x20;yet.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Chemical structures and membrane cholesterol-extracting effects of CDs.</p>
<p> <bold>(A)</bold> CDs typically consist of six, seven, or eight alpha-D-glucopyranoside units, which are referred to as &#x3b1;-, &#x3b2;-, and &#x3b3;CDs. When comparing ring-like structures of conventional and &#x201c;inverted&#x201d; Per(3,6-anhydro)-CDs, the former are characterized by a hydrophobic internal cavity and a hydrophilic outer surface, and different side-chain substitutions fine-tune their chemical properties. M&#x3b2;CD, the most commonly applied derivative for cholesterol depletion <italic>in&#x20;vitro</italic>, is randomly methylated as indicated by R groups in the figure, while HP&#x3b2;CD, the CD most widely used for cholesterol extraction <italic>in vivo</italic>, contains random substitutions with hydroxypropyl groups in these positions. On the other hand, iCDs such as i&#x3b2;CD are single isomers not modified on their glucose hydroxyl groups but their glucose core is itself modified, i.e.,&#x20;the <sup>4</sup>C<sub>1</sub> chair conformation of the natural glucopyranose units are transformed into <sup>1</sup>C<sub>4</sub> form. This modification of the conformation of glucose units causes a dramatic change in lipophilicity profile, as these compounds are characterized by a hydrophilic interior and a hydrophobic outer surface leading to preferential entrapment of hydrophilic guests. <bold>(B)</bold> CHO cells were treated with 1 or 5&#xa0;mM CDs for 1&#xa0;h followed by determination of cholesterol levels using fluorometric cholesterol quantitation kit. While conventional CDs induced dose-dependent decreases in membrane cholesterol contents according to the efficacy order M&#x3b2;CD &#x3e; HP&#x3b2;CD &#x3e; HP&#x3b3;CD, iCDs did not reduce cholesterol levels. <bold>(C)</bold> Kinetics of cholesterol extraction in response to CDs was examined after pre-loading CHO cells with 200&#xa0;&#xb5;M NBD-conjugated cholesterol complexed with M&#x3b2;CD for 1&#xa0;h. Then, time-dependent changes in NBD fluorescence intensities induced by CDs were measured using time-resolved flow cytometry. Treatments started in the sample holder of the flow cytometer immediately before initiation of measurements. Moving averages of time-correlated fluorescence intensity values of approximately 300,000&#xa0;cells per sample were calculated with a window size of 20&#xa0;s and subsequently normalized to average intensities determined in the first time window. Time-dependent reductions in fluorescence intensities were observed in response to all three examined conventional CDs with the efficacy order M&#x3b2;CD &#x3e; HP&#x3b2;CD &#x3e; HP&#x3b3;CD. First significant changes appeared 240, 220, and 300&#xa0;s after the initiation of treatments, respectively. Data are represented as mean&#x20;&#xb1; SEM obtained from <italic>n</italic>&#x20;&#x3d; 6 independent experiments. Asterisks (&#x2a;) indicate significant differences compared to control samples (<italic>p</italic>&#x20;&#x3c; 0.05, ANOVA followed by Tukey&#x2019;s HSD test). For clarity, in panel B every third point is shown and the first time point is marked by an asterisk where significant difference is observed in response to the given treatment.</p>
</caption>
<graphic xlink:href="fmolb-08-735357-g001.tif"/>
</fig>
<p>Recently direct, ligand-like interactions have been demonstrated between CDs and proteins including &#x3b1;-synuclein (<xref ref-type="bibr" rid="B15">Gautam et&#x20;al., 2014</xref>), &#x3b2;-amyloid peptides (<xref ref-type="bibr" rid="B48">Wahlstr&#xf6;m et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B40">Ren et&#x20;al., 2016</xref>), prion proteins (<xref ref-type="bibr" rid="B38">Prior et&#x20;al., 2007</xref>) and AMP-activated protein kinase (<xref ref-type="bibr" rid="B10">Dai et&#x20;al., 2017</xref>), which suggests that CDs might be able to affect the functions of proteins independently of their membrane cholesterol depleting effects as well. Ionic currents of voltage-gated potassium channels (K<sub>V</sub>) are largely influenced by the direct binding of peptide toxins and small molecule inhibitors (<xref ref-type="bibr" rid="B45">Tajti et&#x20;al., 2020</xref>). The actions of these molecules are extensively studied on K<sub>V</sub>1.3, a channel with structural properties and gating mechanisms prototypical for most members of the K<sub>V</sub> family (<xref ref-type="bibr" rid="B29">Liu et&#x20;al., 2021</xref>), and essential functional roles in lymphocytes and microglial cells thus representing an attractive therapeutic target in many autoimmune and neurodegenerative disorders (<xref ref-type="bibr" rid="B13">Feske et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B42">Sarkar et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B39">Ramesha et&#x20;al., 2021</xref>). The operation of K<sub>V</sub> channels is also sensitive to levels of membrane lipids including cholesterol (<xref ref-type="bibr" rid="B6">Bock et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B28">Lipinsky et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B52">Zakany et&#x20;al., 2020</xref>). It has been shown that 1-h incubation with 3&#x2013;5&#xa0;mM&#xa0;M&#x3b2;CD and subsequently decreased cholesterol levels of the cell membrane result in an increase in K<sub>V</sub>1.3 current amplitude, while membrane cholesterol loading with M&#x3b2;CD-cholesterol complexes has opposing effects (<xref ref-type="bibr" rid="B17">Hajd&#xfa; et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B37">PottosinValencia-Cruz et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B3">Balajthy et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B53">Zakany et&#x20;al., 2019</xref>). While most of these studies shedding light on cholesterol effects on K<sub>V</sub>1.3 were carried out with CDs, direct interactions between CDs and K<sub>V</sub> channels have not been investigated previously.</p>
<p>Here, we report on a previously unexplored, direct, ligand-like inhibitory effect of CDs on K<sub>V</sub>1.3 current. Applying inverted, non-cholesterol-extracting per (3,6-anhydro)-CDs as tools for the exclusive examination of ligand-like CD effects during electrophysiological experiments, and performing time-resolved measurements to quantify cholesterol extraction and alterations in membrane fluidity, we demonstrate that this current inhibiting effect is independent of membrane cholesterol depletion and not related to alterations induced in membrane biophysical parameters. <italic>In silico</italic> molecular docking analysis further supported the presence of direct interactions between CDs and the ion channel. Our findings emphasize that potential direct CD effects on K<sub>V</sub> channels should be taken into consideration when interpreting functional consequences of CD treatments in both research and clinical practice. Furthermore, current blocking effects of CDs at therapeutically relevant concentrations in the millimolar range might contribute to additional beneficial or adverse effects during their medical applications.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Cell Culture, Transfection and Cyclodextrins</title>
<p>Chinese hamster ovary (CHO) cells were obtained from the American Type Culture Collection (Manassas, VA) and transfected with wild-type K<sub>V</sub>1.3 and enhanced green fluorescent protein (EGFP) encoding plasmids (OriGene Technologies, MD, United&#x20;States) using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA) as described in <xref ref-type="sec" rid="s10">Supplementary Material</xref>.</p>
<p>Methyl-&#x3b2;-cyclodextrin (M&#x3b2;CD), hydroxypropyl-&#x3b2;-cyclodextrin (HP&#x3b2;CD), hydroxypropyl-&#x3b3;-cyclodextrin (HP&#x3b3;CD), and &#x201c;inverted&#x201d; cyclodextrins (iCDs) including hexakis (3,6-anhydro)-&#x3b1;-cyclodextrin (i&#x3b1;CD), heptakis (3,6-anhydro)-&#x3b2;-cyclodextrin (i&#x3b2;CD) and octakis (3,6-anhydro)-&#x3b3;-cyclodextrin (i&#x3b3;CD) were obtained from CycloLab Cyclodextrin R&#x26;D Laboratory (Budapest, Hungary). For further characterization of iCDs, see <xref ref-type="sec" rid="s10">Supplementary Methods</xref>. In general, cells were treated with CDs dissolved in standard extracellular solution at concentrations of 1 or 5&#xa0;mM at room temperature. Incubation times and other details of CD applications for the given experiments are described in the following sections.</p>
</sec>
<sec id="s2-2">
<title>Quantification of Cellular Cholesterol Content</title>
<p>Cholesterol contents of control samples and those treated with different CDs for 1&#xa0;h were determined using a fluorometric cholesterol quantitation kit (Sigma-Aldrich) according to instructions of the manufacturer with a Synergy HT Microplate Reader (BioTek Instruments, Winooski, VT, United&#x20;States). For kinetic examination of membrane cholesterol extraction, cells were pre-loaded using M&#x3b2;CD complexed with NBD-conjugated cholesterol (25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl]amino]-27-norcholesterol, Avanti Polar Lipids, Alabaster, AL and CycloLab Cyclodextrin R&#x26;D Laboratory) for 1&#xa0;h at a concentration of 195&#xa0;&#xb5;M sterol, followed by incubation with 1 or 5&#xa0;mM of CDs in the sample holder of a NovoCyte 3000RYB flow cytometer (ACEA Biosciences, San Diego, CA) at room temperature. NBD fluorescence intensity was determined using excitation at 488&#xa0;nm and an 530/30&#xa0;nm emission filter. Measurements started immediately after addition of CDs and continued for 10&#xa0;min. Time-correlated fluorescence intensity values were quantified with FCS Express (De Novo Software, Pasadena, CA) and a custom-written Matlab program as described previously (<xref ref-type="bibr" rid="B5">Batta et&#x20;al., 2021</xref>).</p>
</sec>
<sec id="s2-3">
<title>Patch-Clamp Measurements</title>
<p>Patch-clamp measurements were carried out in whole-cell or outside-out configuration using a KF-based pipette solution with a final K<sup>&#x2b;</sup> concentration of 160&#x2013;165&#xa0;mM and a standard extracellular solution containing 150&#xa0;mM NaCl (see also <xref ref-type="sec" rid="s10">Supplementary Material</xref>). CDs were dissolved in standard extracellular solution that were directly applied on the cells with a gravitation propelled perfusion system. The proper working of the perfusion system was validated by applying a high potassium (150&#xa0;mM KCl) containing extracellular solution before the measurement of every single cell to exclude false negative cases originating from the inappropriate flow of CD-containing solutions.</p>
<p>For characterizing direct inhibitory effects of CDs, 15&#xa0;ms depolarizing pulses to &#x2b;50&#xa0;mV were applied every 15&#xa0;s from a holding potential of &#x2013;100&#xa0;mV. The current inhibitory effects of CDs at given concentrations were determined as remaining current fractions (RCF) using the following equation<disp-formula id="e1">
<mml:math id="m1">
<mml:mrow>
<mml:mtext>RCF</mml:mtext>
<mml:mo>&#x3d;</mml:mo>
<mml:mfrac>
<mml:mi>I</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>I</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<label>(1)</label>
</disp-formula>where <italic>I</italic>
<sub>
<italic>0</italic>
</sub> is the leak-corrected peak current in standard extracellular solution before CD applications and <italic>I</italic> is the leak-corrected peak current of the same patch at equilibrium block, at a given CD concentration. To demonstrate the washing-in kinetics of CDs, leak-corrected peak currents at every time point were normalized to the maximal peak. To characterize the extent of washing-out of CDs, recovered current fractions (RF) were determined as a leak-corrected peak current in standard extracellular solution after washing-out the given CDs (I<sub>CD</sub>) over the initial leak-corrected peaks (I<sub>0</sub>) before CD applications according to<disp-formula id="e2">
<mml:math id="m2">
<mml:mrow>
<mml:mtext>RF</mml:mtext>
<mml:mo>&#x3d;</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>I</mml:mi>
<mml:mrow>
<mml:mtext>CD</mml:mtext>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mi>I</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<label>(2)</label>
</disp-formula>
</p>
</sec>
<sec id="s2-4">
<title>Examination of Membrane Biophysical Parameters</title>
<p>To measure changes in membrane fluidity, hydration and lipid order in response to CDs, fluorescence anisotropy of 4&#x2032;-(trimethylammonio)-diphenylhexatriene (TMA-DPH) and generalized polarization (GP) of two indicators, 6-dodecanoyl-N,N-dimethyl-2-naphthylamine (Laurdan) and 4-[2-(6-Dibutylamino-5-fluoro-naphthalen-2-yl)-vinyl]-1-(3-triethylammonio-propyl)-pyridinium dibromide (PY3174), were quantified as described previously and in <xref ref-type="sec" rid="s10">Supplementary Material</xref> (<xref ref-type="bibr" rid="B25">Kwiatek et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B24">Kov&#xe1;cs et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B54">Zakany et&#x20;al., 2021</xref>).</p>
</sec>
<sec id="s2-5">
<title>In silico Molecular Docking Analysis</title>
<p>
<italic>In silico</italic> docking was performed with AutoDock Vina (<xref ref-type="bibr" rid="B46">Trott and Olson, 2009</xref>). The conformation of M&#x3b2;CD was extracted from the crystal structure of the extracellular domain of human Gastric inhibitory polypeptide receptor (PDB 2QKH) that was cocrystallized with M&#x3b2;CD (<xref ref-type="bibr" rid="B36">Parthier et&#x20;al., 2007</xref>). The target of docking was the cryo-electron microscopic structure of K<sub>V</sub>1.3 (PDB 7EJ1) (<xref ref-type="bibr" rid="B29">Liu et&#x20;al., 2021</xref>) and the search space was defined to include the extracellular orifice of the pore domain (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>). AutoDock Vina was run with an exhaustiveness parameter of 40, and ten binding modes were recorded. Amino acids taking part in ligand-target interactions were identified and displayed using LigPlot&#x2b; (<xref ref-type="bibr" rid="B26">Laskowski and Swindells, 2011</xref>) and PyMol.</p>
</sec>
<sec id="s2-6">
<title>Statistical Analysis</title>
<p>Measured data are represented as mean&#x20;&#xb1; SEM obtained from <italic>n</italic> independent samples indicated in figure legends. Differences were considered significant (&#x2a;) when <italic>p</italic>&#x20;&#x3c; 0.05 calculated based on ANOVA followed by Tukey&#x2019;s HSD&#x20;test.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Cholesterol-Extracting Efficiencies and Kinetics of Cyclodextrins</title>
<p>In order to test membrane cholesterol depletion induced by CDs with different cavity charge profiles (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>), we examined cellular cholesterol levels using a commercially available fluorometric cholesterol quantitation kit after treatment of CHO cells with 1 and 5&#xa0;mM of CDs for 1&#xa0;h. In CDs with conventional cavity polarity we obtained data consistent with literature (<xref ref-type="bibr" rid="B55">Zidovetzki and Levitan, 2007</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). M&#x3b2;CD and HP&#x3b2;CD, two derivatives most widely used and most effective in cholesterol extraction, induced significant and comparable dose-dependent decreases in cholesterol levels reaching &#x223c;50% extraction at a concentration of 5&#xa0;mM (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>). HP&#x3b3;CD with much lower affinity for forming complexes with cholesterol also resulted in reduced cholesterol contents, however, these reductions were much smaller thus reaching the level of significance only at 5&#xa0;mM. Concordant with our expectations, iCDs with a hydrophilic cavity did not cause any significant alterations in membrane cholesterol levels.</p>
<p>To characterize the time dependence of cholesterol extraction induced by M&#x3b2;CD, HP&#x3b2;CD, and HP&#x3b3;CD, we preloaded cells with NBD-cholesterol, a fluorophore-conjugated sterol derivative, and examined changes in fluorescence intensities of cells using time-resolved flow cytometry. Treatments with 5&#xa0;mM of CDs started in the sample holder of the flow cytometer immediately before the initiation of measurements. With this technique we were able to follow reductions in levels of exogenous cholesterol molecules incorporated into cellular membranes with a time resolution of 20&#xa0;s in the first 10&#xa0;min of treatments. We observed time-dependent decreases in fluorescence in response to all three examined CDs (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>). Again, consistent with literature, cholesterol-extracting abilities of M&#x3b2;CD and HP&#x3b2;CD were superior to that of HP&#x3b3;CD (<xref ref-type="bibr" rid="B55">Zidovetzki and Levitan, 2007</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). Since only &#x223c;12% of the cholesterol extracted by a 1-h CD treatment was depleted from cells in the first 3&#xa0;min, these experiments suggested that cholesterol depletion in response to conventional CDs is dominant mainly after longer incubation periods. Considering a recent report suggesting similar efficiency of M&#x3b2;CD to extract unlabeled and NBD-cholesterol in living cells (<xref ref-type="bibr" rid="B35">Osta&#x161;ov et&#x20;al., 2013</xref>), this piece of information was utilized for the design of patch-clamp measurements to exclusively separate in time the direct, ligand-like and indirect effects of CDs showing significant cholesterol-depleting abilities.</p>
</sec>
<sec id="s3-2">
<title>Effects of Cyclodextrins on K<sub>V</sub>1.3 Current</title>
<p>The potential direct, ligand-like effect of CDs on K<sub>V</sub>1.3 was tested by patch-clamp. Currents were elicited by 15-ms depolarizing steps to &#x2b;50&#xa0;mV from a holding potential of &#x2013;100&#xa0;mV (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>, top panels) to fully activate K<sub>V</sub>1.3 current (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>, bottom panel, black solid lines). Only those experiments were evaluated, where the proper working of the perfusion apparatus was verified by changes in current parameters in response to high potassium (150&#xa0;mM) solution (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>, grey solid line), which could be subsequently reverted in one step by re-applying standard extracellular solution (not shown for clarity). The exclusive investigation of direct, ligand-like interactions between CDs and K<sub>V</sub>1.3 was ensured in two ways. 1) If patch-clamp measurements are performed in 3&#xa0;minutes after applying the CD-containing extracellular solutions, no significant cholesterol extraction in response to the cholesterol-depleting CDs takes place (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>). 2) Application of i&#x3b1;CD, i&#x3b2;CD and i&#x3b3;CD is a suitable tool for the exclusive examination of direct ligand-like effects of CDs since these derivatives are not able to deplete membrane cholesterol even after 1&#xa0;h (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). As indicated by representative current traces (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>, blue traces) and decreases in RCF values (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>), a current block can be detected in the presence of both 1 and 5&#xa0;mM i&#x3b1;CD. Similarly, M&#x3b2;CD and i&#x3b3;CD also resulted in dose-dependent current blocking effects, as shown by decreases in RCF values, while neither the cholesterol-depleting HP&#x3b2;CD and HP&#x3b3;CD, nor the non-cholesterol-depleting i&#x3b2;CD induced any remarkable changes in RCF (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>). According to the wash-in kinetics for M&#x3b2;CD (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>, black lines), i&#x3b1;CD and i&#x3b3;CD (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref> blue and cyan lines), current-blocking effects were completed within 90&#xa0;s after the initiation of CD exposure in the absence of significant cholesterol depletion according to <xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>. In all three cases, current blocking effects were only partially reversible (<xref ref-type="fig" rid="F2">Figures 2A,B</xref> dotted lines), as indicated by RF values (<xref ref-type="fig" rid="F2">Figure&#x20;2F</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Effects of CDs on K<sub>V</sub>1.3 current.</p>
<p> <bold>(A,B)</bold> Patch-clamp measurements were performed in outside-out or whole-cell configurations in CHO cells transiently expressing K<sub>V</sub>1.3. Two representative measurements with the application of 1mM (panel A) and 5mM (panel B) i&#x3b1;CD are shown. K<sup>&#x2b;</sup> currents were elicited by applying 15ms-long depolarizing pulses from &#x2212;100mV to &#x2b;50mV every 15s (panels A and B, top). First, cells were perfused with standard extracellular solution to obtain control currents (<italic>I</italic>
<sub>
<italic>0</italic>
</sub>, panels A and B, black solid lines). To validate proper working of the perfusion system an extracellular solution with 150mM K<sup>&#x2b;</sup> was applied for each cell prior to CD exposures (panel A, grey line). Cells were perfused with CD-containing extracellular solutions for a maximal application time of 3min to avoid cholesterol-extracting effects of CDs (panels A and B blue lines). Then the reversibility of current-blocking effects induced by the compounds was determined by the reapplication of standard extracellular solution (panel A and B black dotted lines). <bold>(C,D)</bold> To demonstrate the wash-in kinetics of CDs, leak-corrected peak currents at every time point were normalized to the maximal peak. Among cholesterol-depleting CDs, only M&#x3b2;CD in 5mM exhibited a current block (Panel C, black dashed line), while among the non-cholesterol depleting inverted CDs, i&#x3b1;CD (panel D, blue lines) and i&#x3b3;CD (panel D, cyan lines) showed similar effects at both 1mM (solid lines) and 5mM (dashed lines) concentrations. The current blocking effects were saturated within 90s after the initiation of CD exposure in all cases. <bold>(E)</bold> To quantify current-inhibiting effects, remaining current fraction (RCF) values were calculated according to equation (<xref ref-type="bibr" rid="B11">Davis and Brewster, 2004</xref>). The efficacy order of the induced current block was M&#x3b2;CD &#x3c; i&#x3b1;CD &#x3c; i&#x3b3;CD in both concentrations. <bold>(F)</bold> To characterize the extent of wash-out, recovered current fractions (RF) were determined according to equation (<xref ref-type="bibr" rid="B47">Uekama, 2004</xref>). This analysis showed that the current block induced by CDs was only partially reversible. Data represented as mean&#x20;&#xb1; SEM based on <italic>n</italic>&#x20;&#x3d; 4&#x2013;6&#x20;cells.</p>
</caption>
<graphic xlink:href="fmolb-08-735357-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Alterations in Membrane Biophysical Parameters Induced by Cyclodextrins</title>
<p>Although experiments described in the previous section suggest direct interaction between CDs and K<sub>V</sub>1.3 ion channels, we examined whether CDs can possibly exert their effects through changes in biophysical properties of the cell membrane. Therefore, we examined membrane fluidity, hydration and lipid order using environment-sensitive fluorophores. First, to test membrane fluidity, we treated cells with 1 or 5&#xa0;mM CDs for 1&#xa0;h and determined TMA-DPH fluorescence anisotropy negatively correlating with the fluidity of the cell membrane (<xref ref-type="bibr" rid="B5">Batta et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B54">Zakany et&#x20;al., 2021</xref>). As can be expected from the intimate relationship between membrane cholesterol content and fluidity, TMA-DPH fluorescence anisotropy of control cells was significantly decreased by cholesterol-extracting CDs (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). On the other hand, iCDs not capable of depleting membrane cholesterol induced no significant changes in membrane fluidity. Similar effects were observed when examining membrane hydration through quantification of Laurdan GP inversely correlating with membrane hydration (<xref ref-type="bibr" rid="B5">Batta et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B54">Zakany et&#x20;al., 2021</xref>). Laurdan GP of control cells was significantly reduced by CDs causing cholesterol depletion, while it was not affected by iCDs (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>). In order to remove the potential contribution of internalized Laurdan to the measured signal and to ascertain that the calculated GP values reflect the hydration of the plasma membrane where the potassium channels are expressed, membrane lipid order was also investigated with PY3174. Analysis of PY3174 GP, a parameter that positively correlates with the degree of lipid order (<xref ref-type="bibr" rid="B25">Kwiatek et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B54">Zakany et&#x20;al., 2021</xref>), was restricted to the plasma membrane using segmentation of confocal microscopic images. PY3174 GP of control cells was significantly lowered by conventional CDs, but not the inverted derivatives (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effects of CDs on membrane biophysical parameters.</p>
<p> <bold>(A)</bold> CHO cells were treated with 1 or 5&#xa0;mM CDs for 1&#xa0;h, labeled with TMA-DPH and the fluorescence anisotropy of the fluorophore was determined using spectrofluorometry. <bold>(B)</bold> Cells treated as above were alternatively labeled with Laurdan, followed by quantification of generalized polarization (GP) of the dye with spectrofluorometry. <bold>(C)</bold> Control and treated cells were stained with PY3174 and the GP of the dye localized in the cell membrane was subsequently examined using confocal microscopy and quantitative image analysis. Cholesterol-extracting CDs affected biophysical parameters of the cell membrane in the efficacy order M&#x3b2;CD &#x3e; HP&#x3b2;CD &#x3e; HP&#x3b3;CD, as indicated by decreases in TMA-DPH anisotropy implying increased membrane fluidity (A), reductions in Laurdan GP and PY3174 GP referring to increased membrane hydration or lower membrane lipid order (B, C). <bold>(D)</bold> Kinetics of membrane fluidizing effects of CDs was examined after pre-staining CHO cells with TMA-DPH, which was followed by treating them with 5&#xa0;mM of CDs in the cuvette of the spectrofluorometer. Treatments started immediately before initiation of measurements that included repeated quantification of fluorescence anisotropy of the dye every minute in the first 10&#xa0;min of incubation and, as an end-point of the experiments, after 60&#xa0;min. Time-dependent reductions in TMA-DPH anisotropy were observed in response to all three examined conventional CDs with the efficacy order M&#x3b2;CD &#x3e; HP&#x3b2;CD &#x3e; HP&#x3b3;CD. The first significant changes appeared in 8&#xa0;min in response to M&#x3b2;CD and HP&#x3b2;CD, while in the case of HP&#x3b3;CD reductions were significant only after 60&#xa0;min. In the figure, TMA-DPH anisotropy and Laurdan GP values are represented as mean&#x20;&#xb1; SEM obtained from <italic>n</italic>&#x20;&#x3d; 9 independent samples containing approximately 100,000&#xa0;cells. In panel C, mean PY3174 GP values &#xb1;SEM of 20 individual images obtained in five independent experiments are plotted for the different treatments. Each image contained data of 5&#x2013;10&#xa0;cells of normal morphology with a total number of 100&#x2013;200&#xa0;cells per treatment. Asterisks (&#x2a;) indicate significant differences compared to control samples (<italic>p</italic>&#x20;&#x3c; 0.05, ANOVA followed by Tukey&#x2019;s HSD test). For clarity, in panel D the first time point is marked by an asterisk where significant difference is observed in response to the given treatment.</p>
</caption>
<graphic xlink:href="fmolb-08-735357-g003.tif"/>
</fig>
<p>Furthermore, to characterize the time-dependence of changes induced by M&#x3b2;CD, HP&#x3b2;CD and HP&#x3b3;CD in membrane fluidity, we repeated our measurements with TMA-DPH by pre-labeling cells with the fluorophore, which was followed by incubating them with 5&#xa0;mM CDs in the cuvette used in the spectrofluorometer. Treatments started immediately before the initiation of measurements that included repeated quantification of fluorescence anisotropy every minute in the first 10&#xa0;min of incubation and, as an end-point of the experiments, after 60&#xa0;min. Consistent with results of our kinetic cholesterol quantitation experiments, time-dependent reductions were observed in fluorescence anisotropy values for all three examined CDs (<xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>). Membrane fluidizing effects of M&#x3b2;CD and HP&#x3b2;CD were similar and much higher in magnitude than those of HP&#x3b3;CD. For M&#x3b2;CD and HP&#x3b2;CD, significant decreases occurred after 8&#xa0;min, while in the case of HP&#x3b3;CD reductions were not significant in the first 10&#xa0;min. Based on the kinetic traces it could be concluded that only relatively small, 15&#x2013;20% reductions occurred in the first 5&#xa0;min. These data suggest that alterations in membrane biophysical parameters can be expected in response to cholesterol-extracting CDs mainly after longer incubation periods not in the time scale of patch-clamp experiments.</p>
</sec>
<sec id="s3-4">
<title>Potential Mechanisms of Cyclodextrin Actions on K<sub>V</sub>1.3</title>
<p>To quantitatively characterize the correlation between K<sub>V</sub>1.3&#x20;current-inhibiting propensities of the examined CDs and their abilities to deplete membrane cholesterol and modify membrane biophysical parameters, we performed linear regression analysis on results described in previous sections, which were obtained after 1-h incubation in the presence of 5&#xa0;mM CDs. <italic>R</italic>
<sup>2</sup> and <italic>p</italic> values revealed no significant correlation between RCF values determined in patch-clamp measurements and cholesterol levels, TMA-DPH fluorescence anisotropy, Laurdan GP or PY3174 GP values (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>), further supporting the existence of a cholesterol-independent current-blocking effect of certain&#x20;CDs.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Potential mechanisms of CD actions on K<sub>V</sub>1.3.</p>
<p> (<bold>A</bold>) To correlate changes between electrophysiological parameters, cholesterol levels and membrane biophysical parameters, CHO cells were treated with 5&#xa0;mM M&#x3b2;CD, HP&#x3b2;CD, HP&#x3b3;CD, i&#x3b1;CD, i&#x3b2;CD or i&#x3b3;CD for 1&#xa0;h, which was followed by determination of K<sub>V</sub>1.3 remaining current fraction (RCF), cholesterol level, TMA-DPH fluorescence anisotropy, and Laurdan and PY3174 generalized polarization (GP), as described previously in detail. Average values (&#xb1;SEM) of cholesterol level, TMA-DPH fluorescence anisotropy, Laurdan GP and PY3174 GP were plotted as function of RCF values. <italic>R</italic>
<sup>2</sup> and <italic>p</italic> values determined with linear regression analysis are shown in the panels, which revealed no significant correlation between RCF and any of the other examined parameters. (<bold>B</bold>) To examine possible direct interactions between CDs and K<sub>V</sub>1.3, <italic>in silico</italic> molecular docking was performed with AutoDock Vina using M&#x3b2;CD (from structure PDB 2QKH (black)) and the cryo-electron microscopic structure of Kv1.3 (PDB 7EJ1). S1-S6 transmembrane helices of different subunits are shown in different colors, while the rest of the channel (tetramerization domain) is displayed in grey. One representative binding mode of M&#x3b2;CD to the extracellular surface of the pore domain is shown in the upper panel. Amino acids taking part in ligand-target interactions were identified and displayed using LigPlot&#x2b; and PyMol. The identified hydrogen bonds are illustrated with red lines, while hydrophobic interactions are labeled by shaded areas between M&#x3b2;CD and K<sub>V</sub>1.3. Amino acid residues taking part in hydrogen bonds are shown in bold, while those involved in hydrophobic interactions are represented in italic.</p>
</caption>
<graphic xlink:href="fmolb-08-735357-g004.tif"/>
</fig>
<p>Furthermore, to examine potential direct interactions between CDs and K<sub>V</sub>1.3, we performed <italic>in silico</italic> molecular docking analysis between M&#x3b2;CD and Kv1.3 (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>). Since electrophysiological evidence argues against binding of M&#x3b2;CD intracellularly (current-inhibiting effects of all CDs appeared in 15&#xa0;s and completed within 90&#xa0;s) or to the voltage-sensor (no shift in activation threshold, data not shown), the extracellular orifice of the pore domain was chosen as a search space for docking covering the most frequent binding sites of toxins and small molecule inhibitors (<xref ref-type="bibr" rid="B23">Kavanaugh et&#x20;al., 1991</xref>; <xref ref-type="bibr" rid="B19">Holmgren et&#x20;al., 1997</xref>; <xref ref-type="bibr" rid="B16">Gilquin et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B22">Karbat et&#x20;al., 2019</xref>) (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>). Ten binding modes were recorded, which were characterized by estimated K<sub>d</sub>s consistent with the dose-dependence of current inhibition described above (binding affinities were in the range of &#x2212;4.3 to &#x2212;3.9&#xa0;kcal/mol corresponding to estimated K<sub>d</sub> values between 618 and 1,229&#xa0;&#xb5;M). These modes identified a common pattern of direct binding involving a network of hydrogen bonds and hydrophobic interactions between M&#x3b2;CD and pore residues. The association was typically mediated by hydrogen bonds formed by His399, Gly396 and Thr373 or Asp397, and hydrophobic interactions through Asp397, Gly375 or Tyr395 of one subunit. The structure was usually further stabilized by a hydrogen bond with His399 and hydrophobic interaction with Gly396 on the adjacent subunit, and additional hydrophobic interactions with Gly396 and Asp397 of the opposing subunit (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Due to their unique chemical structure providing the basis for forming water-soluble complexes of otherwise non-soluble lipids and drugs, CDs are extensively used in both research and clinical applications (<xref ref-type="bibr" rid="B11">Davis and Brewster, 2004</xref>; <xref ref-type="bibr" rid="B47">Uekama, 2004</xref>; <xref ref-type="bibr" rid="B30">Loftsson et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B43">Szente and Fenyvesi, 2017</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). According to <italic>in&#x20;vitro</italic> studies (<xref ref-type="bibr" rid="B43">Szente and Fenyvesi, 2017</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>) and our experiments as well, M&#x3b2;CD has the highest affinity to deplete cholesterol from the membrane of living cells (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>), which ensures its popularity in the laboratory practice. On the contrary, M&#x3b2;CD cannot be applied parenterally in clinical practice due to its <italic>in vivo</italic> hemolytic effect (<xref ref-type="bibr" rid="B20">Irie et&#x20;al., 1982</xref>; <xref ref-type="bibr" rid="B34">Ohtani et&#x20;al., 1989</xref>). Thus, HP&#x3b2;CD is the first choice to deplete membrane cholesterol in medical practice due to its increased biological tolerability (<xref ref-type="bibr" rid="B21">Irie and Uekama, 1997</xref>; <xref ref-type="bibr" rid="B44">Szente et&#x20;al., 2018</xref>). HP&#x3b2;CD got recently into the focus of many ongoing clinical trials since it received an orphan drug status for the treatment of NPC disease by Food and Drug Administration (<xref ref-type="bibr" rid="B31">Matencio et&#x20;al., 2020</xref>), further corroborating the increasing potential of CDs in therapeutic applications.</p>
<p>M&#x3b2;CD alone or pre-complexed with cholesterol is typically employed for 1&#xa0;h with concentrations ranging from 3 up to 10&#xa0;mM (<xref ref-type="bibr" rid="B55">Zidovetzki and Levitan, 2007</xref>). Local CD concentrations of comparable magnitude can also be reached in medical use. For example, due to its poor blood-brain barrier penetration ability and short biological half-life, the dosage of HP&#x3b2;CD in the treatment of NPC disease is extremely high (1,200&#x2013;2,500&#xa0;mg/kg/week) (<xref ref-type="bibr" rid="B32">Megias-Vericat et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B8">Carradori et&#x20;al., 2020</xref>). This protocol leads to the incidence of severe side effects including chemical meningitis and sensorineural hearing loss (<xref ref-type="bibr" rid="B9">Crumling et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B32">Megias-Vericat et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B18">Hammond et&#x20;al., 2019</xref>). While both beneficial and adverse effects of CDs are generally thought to originate from their cholesterol-extracting actions, direct interactions with K<sub>V</sub> channels might also contribute to their effects.</p>
<p>CDs can influence the function of proteins in two distinct ways. On one hand, as the structure and function of transmembrane proteins are substantially influenced by cholesterol, CDs can modify protein functions through alterations in cholesterol levels and related membrane biophysical parameters (<xref ref-type="bibr" rid="B52">Zakany et&#x20;al., 2020</xref>). On the other hand, CDs can affect proteins through direct, ligand-like interactions mediated through binding to their aromatic amino acid residues including tyrosine, phenylalanine, tryptophan and possibly histidine as demonstrated recently for many proteins (<xref ref-type="bibr" rid="B1">Aachmann et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B38">Prior et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B48">Wahlstr&#xf6;m et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B40">Ren et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B10">Dai et&#x20;al., 2017</xref>). In these cases, the suggested mechanism involves mainly hydrophobic and van der Waals interactions resulting in the inclusion of these residues into the hydrophobic cavity of CDs, and the association properties are determined by shape-matching and optimum hydrophobicity conditions (<xref ref-type="bibr" rid="B14">Gautam et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B33">Niccoli et&#x20;al., 2017</xref>). Furthermore, CDs were recently proposed to also interact with other amino acids including Asp, Asn, Lys or even His through hydrogen bonds, and the binding orientation of CD might depend on its possible chemical substitutions and the given interacting residue (<xref ref-type="bibr" rid="B4">Banerjee et&#x20;al., 2010</xref>). Numerous studies investigated the effects of CDs on K<sub>V</sub>1.3, a prototypical and pathophysiologically relevant K<sub>V</sub> channel, substantially affected by cholesterol (<xref ref-type="bibr" rid="B17">Hajd&#xfa; et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B37">PottosinValencia-Cruz et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B3">Balajthy et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B53">Zakany et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B52">Zakany et&#x20;al., 2020</xref>), however these studies focused solely on cholesterol-mediated actions and examination of direct interaction between CDs and K<sub>V</sub>1.3 has not been reported yet. In this aspect, interaction between CDs and K<sub>V</sub>s might be similar to those between polyunsaturated fatty acids and these channels. Although the effect of polyunsaturated fatty acids have long been considered to be mediated indirectly by modulating the biophysical properties of membranes, recent studies demonstrated direct binding of these lipids to members of the K<sub>V</sub>7 family leading to substantial alterations in its electrophysiological parameters (<xref ref-type="bibr" rid="B27">Liin et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B51">Yazdi et&#x20;al., 2021</xref>).</p>
<p>In this study we report on direct, ligand-like inhibitory effect of CDs on the K<sub>V</sub>1.3 ion channel at biologically relevant millimolar concentrations, which is independent of membrane cholesterol depletion and concomitant alterations in membrane biophysical parameters caused by CDs. Based on our results, this hypothesis is supported by the following arguments: 1) According to literature data cholesterol depletion by 1-h M&#x3b2;CD treatment results in an increase in K<sub>V</sub>1.3 current, while we detected current inhibition by M&#x3b2;CD completed within 90&#xa0;s (<xref ref-type="fig" rid="F2">Figures 2C,E</xref>). 2) Cholesterol-depleting and current-inhibiting abilities of CDs are not in parallel since M&#x3b2;CD, i&#x3b1;CD and i&#x3b3;CD were able to block Kv1.3 currents (<xref ref-type="fig" rid="F2">Figures 2C,D,E</xref>), while only M&#x3b2;CD exhibited significant cholesterol extraction after longer exposure (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref> and <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). On the other hand, cholesterol-depleting HP&#x3b2;CD and HP&#x3b3;CD (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>) did not inhibit currents (<xref ref-type="fig" rid="F2">Figures 2C,E</xref>, <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). 3) Similarly to cholesterol extraction, K<sub>V</sub>1.3 current inhibition showed no correlation with alterations in membrane biophysical parameters including fluidity, hydration and lipid order (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>, <xref ref-type="fig" rid="F3">Figure&#x20;3</xref> and <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). 4) Ion channel blockade in response to cholesterol-extracting M&#x3b2;CD was completed on a time-scale where no significant changes were observed in membrane cholesterol level or fluidity (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>, <xref ref-type="fig" rid="F2">Figure&#x20;2C</xref> and <xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>). 5) Current inhibitory effects of M&#x3b2;CD, i&#x3b1;CD and i&#x3b3;CD were dose-dependent at concentrations that are comparable in magnitude with those reached in blood during parenteral administration of CD-containing medications or when used in research to modify membrane cholesterol levels (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>). 6) Consistent with our electrophysiological data, molecular docking analysis revealed potential direct interactions between M&#x3b2;CD and the extracellular part of the pore domain of K<sub>V</sub>1.3 (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>).</p>
<p>Although the patch-clamp measurements did not shed light on the binding site of CDs in K<sub>V</sub>1.3, the kinetics of current block may provide a hint whether they bind to an intra- or extracellular location. According to our results the blocking effects of the tested CDs appeared in 15&#xa0;s and completed within 90&#xa0;s (<xref ref-type="fig" rid="F2">Figures 2C,D</xref>). Given that CDs are generally considered to enter cells via endocytic mechanisms (<xref ref-type="bibr" rid="B41">Rosenbaum et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B12">Fenyvesi et&#x20;al., 2014</xref>), this suggests that CDs are more likely to bind to the extracellular surface of the channel. The generally known pore blockers have three potential binding regions on K<sub>V</sub> channels: the intracellular cavity (residue Ile420 in K<sub>V</sub>1.3) (<xref ref-type="bibr" rid="B19">Holmgren et&#x20;al., 1997</xref>), the extracellular mouth of the pore (residue His399) (<xref ref-type="bibr" rid="B23">Kavanaugh et&#x20;al., 1991</xref>; <xref ref-type="bibr" rid="B16">Gilquin et&#x20;al., 2005</xref>), and the turret region (residue Gly375) (<xref ref-type="bibr" rid="B22">Karbat et&#x20;al., 2019</xref>). Supporting direct binding of CDs to the extracellular surface of the pore domain of the channel, our molecular docking analysis identified potential M&#x3b2;CD binding sites organized mainly by His399 of neighboring subunits (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>), however, interactions of the identified residues with other CDs and their physiological relevance should be tested by future studies applying specific mutations. Furthermore, our results do not provide an unequivocal mechanism of CD effects, i.e.,&#x20;whether CDs directly plug the orifice of the pore or rather induce a conformational change resulting in the block of ion conduction. Thus, inhibitors selectively interacting with these sites could provide additional relevant information to fully characterize the mechanism of direct current-inhibiting actions of CDs on K<sub>V</sub> channels. Interestingly, while i&#x3b1;CD and i&#x3b3;CD efficiently blocked K<sub>V</sub>1.3, i&#x3b2;CD failed to inhibit ion conduction. Although a reliable explanation for the distinctive behavior of iCDs is not possible based on our findings, it can originate from differences in their size and hydrophobicity profile, binding affinity, site and/or orientation, which can result in its inability to physically occlude the pore or induce conformational changes in this region leading to channel&#x20;block.</p>
<p>Our results propose that direct blocking effects of CDs exerted on K<sub>V</sub> channels may have physiological consequences during their clinical and research applications. In the future, identifying direct interactions of CDs with various proteins including other members of the K<sub>V</sub> family and elucidating their mechanism of binding can provide significant improvements in the understanding of the beneficial and adverse effects of CD-containing medications and contribute to the chemical design of CDs with more favorable effect profile.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>TK&#x2014;Conceptualization, Investigation, Methodology, Formal analysis, Visualization, Writing&#x2014;Original draft preparation, TS&#x2014;Resources, LS&#x2014;Resources, PN&#x2014;Methodology, Writing&#x2014;Review and editing, GP&#x2014;Funding, Writing&#x2014;Review and editing, ZV&#x2014;Conceptualization, Methodology, Supervision, Funding, Writing&#x2014;Review and editing, FZ&#x2014;Conceptualization, Investigation, Methodology, Formal analysis, Visualization, Supervision, Project administration, Funding, Writing&#x2014;Original draft preparation, Writing&#x2014;Review and editing</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by the UNKP-19-3-III-DE-92 (FZ), UNKP-21-4-II-DE-138 (FZ) and UNKP-21-4-II-DE-137 (TK) New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund, the Ministry of Human Capacities (NTP-NFT&#xd6;-20-B-0115, FZ; Hungary grant EFOP-3.6.1-16-2016-00022, GP), the Ministry of Finance (Hungary grant GINOP-2.3.2-15-2016-00044, GP), the National Research, Development and Innovation Office (OTKA K132906 and SNN139532, ZV; OTKA K119417, GP; OTKA K138075 and ANN133421, PN; 2019-2.1.11-T&#xc9;T-2019-00059, ZV) and by 2020-1.1.2-PIACI-KFI-2020-00092 (TS, LS). The project is co-financed by the European Union and the European Regional Development&#x20;Fund.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>TS and LS was employed by the CycloLab Cyclodextrin R and D Laboratory&#x20;Ltd.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We thank the expert technical assistance of Adrienn Bagosi.</p>
</ack>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2021.735357/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2021.735357/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<sec id="s11">
<title>Abbreviations</title>
<p>AMP, adenosine monophosphate; ANOVA, analysis of variance; CD, cyclodextrin; CHO, Chinese hamster ovary cell; GP, generalized polarization, HP&#x3b2;CD, hydroxypropyl-&#x3b2;-cyclodextrin; HP&#x3b3;CD, hydroxypropyl-&#x3b3;-cyclodextrin; iCD, &#x2018;inverted&#x2019; Per(3,6-anhydro)-cyclodextrin; i&#x3b1;CD, hexakis (3,6 anhydro)-&#x3b1;-cyclodextrin; i&#x3b2;CD, heptakis (3,6 anhydro)-&#x3b2;-cyclodextrin; i&#x3b3;CD, octakis (3,6 anhydro)-&#x3b3;-cyclodextrin; K<sub>V</sub>, voltage-gated potassium channel; Laurdan, 6-dodecanoyl-N,N-dimethyl-2-naphthylamine; M&#x3b2;CD, methyl-&#x3b2;-cyclodextrin; NBD, cholesterol: 25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl]amino]-27-norcholesterol; NPC, Niemann-Pick type C disease; PY3174: di-4-AN(F)EPPTEA; 4-[2-(6-Dibutylamino-5-fluoro-naphthalen-2-yl)-vinyl]-1-(3-triethylammonio-propyl)-pyridinium dibromide; RCF, remaining current fraction; RF, recovered current fraction; TMA-DPH, 4&#x2032;-(trimethylammonio)-diphenylhexatriene.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aachmann</surname>
<given-names>F. L.</given-names>
</name>
<name>
<surname>Otzen</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Structural Background of Cyclodextrin-Protein Interactions</article-title>. <source>Protein Eng. Des. Selection</source> <volume>16</volume> (<issue>12</issue>), <fpage>905</fpage>&#x2013;<lpage>912</lpage>. <pub-id pub-id-type="doi">10.1093/protein/gzg137</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashton</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Gattuso</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>K&#xf6;niger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stoddart</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Dipotassium Complex of Per-3,6-Anhydro-&#x3b2;-Cyclodextrin</article-title>. <source>J.&#x20;Org. Chem.</source> <volume>61</volume> (<issue>26</issue>), <fpage>9553</fpage>&#x2013;<lpage>9555</lpage>. <pub-id pub-id-type="doi">10.1021/jo9615357</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balajthy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Somodi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peth&#x151;</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>P&#xe9;ter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Szab&#xf3;</surname>
<given-names>G. P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>7DHC-induced Changes of Kv1.3 Operation Contributes to Modified T&#x20;Cell Function in Smith-Lemli-Opitz Syndrome</article-title>. <source>Pflugers Arch. - Eur. J.&#x20;Physiol.</source> <volume>468</volume> (<issue>8</issue>), <fpage>1403</fpage>&#x2013;<lpage>1418</lpage>. <pub-id pub-id-type="doi">10.1007/s00424-016-1851-4</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banerjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mikhailova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cheley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>L.-Q.</given-names>
</name>
<name>
<surname>Montoya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nagaoka</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Molecular Bases of Cyclodextrin Adapter Interactions with Engineered Protein Nanopores</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>107</volume> (<issue>18</issue>), <fpage>8165</fpage>&#x2013;<lpage>8170</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0914229107</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>K&#xe1;rp&#xe1;ti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Henrique</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>T&#xf3;th</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tarapcs&#xe1;k</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Statin&#x2010;boosted Cellular Uptake and Endosomal Escape of Penetratin Due to Reduced Membrane Dipole Potential</article-title>. <source>Br. J.&#x20;Pharmacol.</source> <volume>178</volume>, <fpage>3667</fpage>&#x2013;<lpage>3681</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15509</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bock</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Szab&#xf3;</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gamper</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gulbins</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Ceramide Inhibits the Potassium Channel Kv1.3 by the Formation of Membrane Platforms</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>305</volume> (<issue>4</issue>), <fpage>890</fpage>&#x2013;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-291x(03)00763-0</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukiya</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Leo</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Jaggar</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Dopico</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cholesterol Activates BK Channels by Increasing KCNMB1 Protein Levels in the Plasmalemma</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>296</volume>, <fpage>100381</fpage>. <pub-id pub-id-type="doi">10.1016/j.jbc.2021.100381</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carradori</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Leonardi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Usuelli</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann&#x2010;Pick Disease Type C Using Crosslinked 2&#x2010;Hydroxypropyl&#x2010;&#x3b2;&#x2010;cyclodextrin</article-title>. <source>Small</source> <volume>16</volume> (<issue>46</issue>), <fpage>2004735</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202004735</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crumling</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk</article-title>. <source>Front. Cel. Neurosci.</source> <volume>11</volume>, <fpage>355</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00355</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dulcey</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wassif</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>F. D.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>C. P.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Methyl-&#x3b2;-cyclodextrin Restores Impaired Autophagy Flux in Niemann-Pick C1-Deficient Cells through Activation of AMPK</article-title>. <source>Autophagy</source> <volume>13</volume> (<issue>8</issue>), <fpage>1435</fpage>&#x2013;<lpage>1451</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2017.1329081</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Brewster</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Cyclodextrin-based Pharmaceutics: Past, Present and Future</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>3</volume> (<issue>12</issue>), <fpage>1023</fpage>&#x2013;<lpage>1035</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1576</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fenyvesi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>R&#xe9;ti-Nagy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bacs&#xf3;</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gutay-T&#xf3;th</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Malanga</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fenyvesi</surname>
<given-names>&#xc9;.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Fluorescently Labeled Methyl-Beta-Cyclodextrin Enters Intestinal Epithelial Caco-2 Cells by Fluid-phase Endocytosis</article-title>. <source>PLoS One</source> <volume>9</volume> (<issue>1</issue>), <fpage>e84856</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0084856</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feske</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wulff</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Skolnik</surname>
<given-names>E. Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Ion Channels in Innate and Adaptive Immunity</article-title>. <source>Annu. Rev. Immunol.</source> <volume>33</volume>, <fpage>291</fpage>&#x2013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112212</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gautam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karmakar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pradhan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Polyphenols in Combination with &#x3b2;-cyclodextrin Can Inhibit and Disaggregate &#x3b1;-synuclein Amyloids under Cell Mimicking Conditions: A Promising Therapeutic Alternative</article-title>. <source>Biochim. Biophys. Acta (Bba) - Proteins Proteomics</source> <volume>1865</volume> (<issue>5</issue>), <fpage>589</fpage>&#x2013;<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2017.02.014</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gautam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karmakar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bose</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>P. K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>&#x3b2;-Cyclodextrin and Curcumin, a Potent Cocktail for Disaggregating And/or Inhibiting Amyloids: A Case Study with &#x3b1;-Synuclein</article-title>. <source>Biochemistry</source> <volume>53</volume> (<issue>25</issue>), <fpage>4081</fpage>&#x2013;<lpage>4083</lpage>. <pub-id pub-id-type="doi">10.1021/bi500642f</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilquin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Braud</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>M. A. L.</given-names>
</name>
<name>
<surname>Roux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Priest</surname>
<given-names>B. T.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>A Variable Residue in the Pore of Kv1 Channels Is Critical for the High Affinity of Blockers from Sea Anemones and Scorpions</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>280</volume> (<issue>29</issue>), <fpage>27093</fpage>&#x2013;<lpage>27102</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M413626200</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hajd&#xfa;</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pieri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Panyi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>G&#xe1;sp&#xe1;r</surname>
<given-names>R.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>2003</year>). <article-title>Cholesterol Modifies the Gating of Kv1.3 in Human T Lymphocytes</article-title>. <source>Pflugers Arch. - Eur. J.&#x20;Physiol.</source> <volume>445</volume> (<issue>6</issue>), <fpage>674</fpage>&#x2013;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1007/s00424-002-0974-y</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammond</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Munkacsi</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Sturley</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Complexity of a Monogenic Neurodegenerative Disease: More Than Two Decades of Therapeutic Driven Research into Niemann-Pick Type C Disease</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Cel Biol. Lipids</source> <volume>1864</volume> (<issue>8</issue>), <fpage>1109</fpage>&#x2013;<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2019.04.002</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmgren</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Yellen</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Trapping of Organic Blockers by Closing of Voltage-dependent K&#x2b; Channels</article-title>. <source>J.&#x20;Gen. Physiol.</source> <volume>109</volume> (<issue>5</issue>), <fpage>527</fpage>&#x2013;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.109.5.527</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Otagiri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sunada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Uekama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohtani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>1982</year>). <article-title>Cyclodextrin-induced Hemolysis and Shape Changes of Human Erythrocytes <italic>In Vitro</italic>
</article-title>. <source>J.&#x20;Pharmacobio-Dynamics</source> <volume>5</volume> (<issue>9</issue>), <fpage>741</fpage>&#x2013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1248/bpb1978.5.741</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Uekama</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation</article-title>. <source>J.&#x20;Pharm. Sci.</source> <volume>86</volume> (<issue>2</issue>), <fpage>147</fpage>&#x2013;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1021/js960213f</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karbat</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Altman-Gueta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fine</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Szanto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hamer-Rogotner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dym</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Pore-modulating Toxins Exploit Inherent Slow Inactivation to Block K&#x2b;channels</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>116</volume> (<issue>37</issue>), <fpage>18700</fpage>&#x2013;<lpage>18709</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1908903116</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavanaugh</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Varnum</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Christie</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Busch</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Adelman</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<etal/>
</person-group> (<year>1991</year>). <article-title>Interaction between Tetraethylammonium and Amino Acid Residues in the Pore of Cloned Voltage-dependent Potassium Channels</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>266</volume> (<issue>12</issue>), <fpage>7583</fpage>&#x2013;<lpage>7587</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(20)89487-3</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kov&#xe1;cs</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Batta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Z&#xe1;k&#xe1;ny</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sz&#xf6;ll&#x151;si</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Dipole Potential Correlates with Lipid Raft Markers in the Plasma Membrane of Living Cells</article-title>. <source>J.&#x20;Lipid Res.</source> <volume>58</volume> (<issue>8</issue>), <fpage>1681</fpage>&#x2013;<lpage>1691</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M077339</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwiatek</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Abu-Siniyeh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Loew</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Gaus</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Characterization of a New Series of Fluorescent Probes for Imaging Membrane Order</article-title>. <source>PLoS One</source> <volume>8</volume> (<issue>2</issue>), <fpage>e52960</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0052960</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskowski</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Swindells</surname>
<given-names>M. B.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>LigPlot&#x2b;: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery</article-title>. <source>J.&#x20;Chem. Inf. Model.</source> <volume>51</volume> (<issue>10</issue>), <fpage>2778</fpage>&#x2013;<lpage>2786</lpage>. <pub-id pub-id-type="doi">10.1021/ci200227u</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liin</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Yazdi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramentol</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Barro-Soria</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>H. P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mechanisms Underlying the Dual Effect of Polyunsaturated Fatty Acid Analogs on Kv7.1</article-title>. <source>Cel Rep.</source> <volume>24</volume> (<issue>11</issue>), <fpage>2908</fpage>&#x2013;<lpage>2918</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.031</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipinsky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tobelaim</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Peretz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Simhaev</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yeheskel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yakubovich</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Unique Mechanism of Inactivation Gating of the Kv Channel Family Member Kv7.1 and its Modulation by PIP2 and Calmodulin</article-title>. <source>Sci. Adv.</source> <volume>6</volume> (<issue>51</issue>). <pub-id pub-id-type="doi">10.1126/sciadv.abd6922</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Structures of Wild-type and H451N Mutant Human Lymphocyte Potassium Channel KV1.3</article-title>. <source>Cell Discov</source> <volume>7</volume> (<issue>1</issue>), <fpage>39</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-021-00269-y</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loftsson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jarho</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>M&#xe1;sson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>J&#xe4;rvinen</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Cyclodextrins in Drug Delivery</article-title>. <source>Expert Opin. Drug Deliv.</source> <volume>2</volume> (<issue>2</issue>), <fpage>335</fpage>&#x2013;<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1517/17425247.2.1.335</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matencio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Navarro-Orcajada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez-Ram&#xf3;n</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Carmona</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Nicol&#xe1;s</surname>
<given-names>J.&#x20;M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Recent Advances in the Treatment of Niemann Pick Disease Type C: A Mini-Review</article-title>. <source>Int. J.&#x20;Pharmaceutics</source> <volume>584</volume>, <fpage>119440</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119440</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Megias-Vericat</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Company-Albir</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Garcia-Robles</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Poveda</surname>
<given-names>J.&#x20;L.</given-names>
</name>
</person-group> (<year>2017</year>). &#x201c;<article-title>Use of 2-Hydroxypropyl-Beta-Cyclodextrin for Niemann-Pick Type C Disease</article-title>,&#x201d; in <source>Cyclodextrin - A Versatile Ingredient</source>. Editors <person-group person-group-type="editor">
<name>
<surname>Arora</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dhingra</surname>
<given-names>N.</given-names>
</name>
</person-group> (<publisher-loc>London, UK</publisher-loc>: <publisher-name>IntechOpen</publisher-name>). </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niccoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oliva</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Castronuovo</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cyclodextrin-protein Interaction as Inhibiting Factor against Aggregation</article-title>. <source>J.&#x20;Therm. Anal. Calorim.</source> <volume>127</volume> (<issue>2</issue>), <fpage>1491</fpage>&#x2013;<lpage>1499</lpage>. <pub-id pub-id-type="doi">10.1007/s10973-016-5736-8</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohtani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Irie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Uekama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pitha</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Differential Effects of Alpha-, Beta- and Gamma-Cyclodextrins on Human Erythrocytes</article-title>. <source>Eur. J.&#x20;Biochem.</source> <volume>186</volume> (<issue>1-2</issue>), <fpage>17</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1989.tb15171.x</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osta&#x161;ov</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>S&#xfd;kora</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brejchov&#xe1;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ol&#x17c;y&#x144;ska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Svoboda</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>FLIM Studies of 22- and 25-NBD-Cholesterol in Living HEK293 Cells: Plasma Membrane Change Induced by Cholesterol Depletion</article-title>. <source>Chem. Phys. Lipids</source> <volume>167-168</volume>, <fpage>62</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.chemphyslip.2013.02.006</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parthier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kleinschmidt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Manhart</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schlenzig</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Crystal Structure of the Incretin-Bound Extracellular Domain of a G Protein-Coupled Receptor</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>104</volume> (<issue>35</issue>), <fpage>13942</fpage>&#x2013;<lpage>13947</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0706404104</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pottosin</surname>
<suffix>II.</suffix>
</name>
<name>
<surname>Valencia-Cruz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bonales-Alatorre</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shabala</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Dobrovinskaya</surname>
<given-names>O. R.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Methyl-&#x3b2;-cyclodextrin Reversibly Alters the Gating of Lipid Rafts-Associated Kv1.3 Channels in Jurkat T Lymphocytes</article-title>. <source>Pflugers Arch. - Eur. J.&#x20;Physiol.</source> <volume>454</volume> (<issue>2</issue>), <fpage>235</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1007/s00424-007-0208-4</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prior</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sy</surname>
<given-names>M.-S.</given-names>
</name>
<name>
<surname>Molloy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>H. E. M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Cyclodextrins Inhibit Replication of Scrapie Prion Protein in Cell Culture</article-title>. <source>J.&#x20;Virol.</source> <volume>81</volume> (<issue>20</issue>), <fpage>11195</fpage>&#x2013;<lpage>11207</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02559-06</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramesha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rayaprolu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Giver</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Bitarafan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>H. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Unique Molecular Characteristics and Microglial Origin of Kv1.3&#x20;Channel-Positive Brain Myeloid Cells in Alzheimer&#x27;s Disease</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>118</volume> (<issue>11</issue>), <fpage>e2013545118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2013545118</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>HP-&#x3b2;-cyclodextrin as an Inhibitor of Amyloid-&#x3b2; Aggregation and Toxicity</article-title>. <source>Phys. Chem. Chem. Phys.</source> <volume>18</volume> (<issue>30</issue>), <fpage>20476</fpage>&#x2013;<lpage>20485</lpage>. <pub-id pub-id-type="doi">10.1039/c6cp03582e</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenbaum</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Maxfield</surname>
<given-names>F. R.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Endocytosis of Beta-Cyclodextrins Is Responsible for Cholesterol Reduction in Niemann-Pick Type C Mutant Cells</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>107</volume> (<issue>12</issue>), <fpage>5477</fpage>&#x2013;<lpage>5482</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0914309107</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Malovic</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Langley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Palanisamy</surname>
<given-names>B. N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Kv1.3 Modulates Neuroinflammation and Neurodegeneration in Parkinson&#x27;s Disease</article-title>. <source>J.&#x20;Clin. Invest.</source> <volume>130</volume> (<issue>8</issue>), <fpage>4195</fpage>&#x2013;<lpage>4212</lpage>. <pub-id pub-id-type="doi">10.1172/JCI136174</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szente</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fenyvesi</surname>
<given-names>&#xc9;.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cyclodextrin-Lipid Complexes: Cavity Size Matters</article-title>. <source>Struct. Chem.</source> <volume>28</volume> (<issue>2</issue>), <fpage>479</fpage>&#x2013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1007/s11224-016-0884-9</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szente</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Domokos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis</article-title>. <source>Molecules</source> <volume>23</volume> (<issue>5</issue>), <fpage>1228</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23051228</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tajti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wai</surname>
<given-names>D. C. C.</given-names>
</name>
<name>
<surname>Panyi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Voltage-Gated Potassium Channel KV1.3 as a Therapeutic Target for Venom-Derived Peptides</article-title>. <source>Biochem. Pharmacol.</source> <volume>181</volume>, <fpage>114146</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2020.114146</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trott</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>31</volume> (<issue>2</issue>), <fpage>445</fpage>-<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uekama</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Design and Evaluation of Cyclodextrin-Based Drug Formulation</article-title>. <source>Chem. Pharm. Bull.</source> <volume>52</volume> (<issue>8</issue>), <fpage>900</fpage>&#x2013;<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1248/cpb.52.900</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahlstr&#xf6;m</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cukalevski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Danielsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jarvet</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Onagi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rebek</surname>
<given-names>J.</given-names>
<suffix>Jr.</suffix>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Specific Binding of a &#x3b2;-Cyclodextrin Dimer to the Amyloid &#x3b2; Peptide Modulates the Peptide Aggregation Process</article-title>. <source>Biochemistry</source> <volume>51</volume> (<issue>21</issue>), <fpage>4280</fpage>&#x2013;<lpage>4289</lpage>. <pub-id pub-id-type="doi">10.1021/bi300341j</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ishitsuka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakahara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takeo</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Differential Mode of Cholesterol Inclusion with 2&#x2010;hydroxypropyl&#x2010;cyclodextrins Increases Safety Margin in Treatment of Niemann&#x2010;Pick Disease Type C</article-title>. <source>Br. J.&#x20;Pharmacol.</source> <volume>178</volume> (<issue>13</issue>), <fpage>2727</fpage>&#x2013;<lpage>2746</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15464</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ezuka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Butsugan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Preparation of Octakis(3,6-Anhydro)-&#x3b3;-Cyclodextrin and Characterization of its Cation Binding Ability</article-title>. <source>J.&#x20;Chem. Soc. Chem. Commun.</source> (<issue>7</issue>), <fpage>636</fpage>&#x2013;<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1039/C39930000636</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yazdi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nikesj&#xf6;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Corradi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tieleman</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Noskov</surname>
<given-names>S. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Identification of PUFA Interaction Sites on the Cardiac Potassium Channel KCNQ1</article-title>. <source>J.&#x20;Gen. Physiol.</source> <volume>153</volume> (<issue>6</issue>), <fpage>e202012850</fpage>. <pub-id pub-id-type="doi">10.1085/jgp.202012850</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zakany</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Panyi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Direct and Indirect Cholesterol Effects on Membrane Proteins with Special Focus on Potassium Channels</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Cel Biol. Lipids</source> <volume>1865</volume> (<issue>8</issue>), <fpage>158706</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2020.158706</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zakany</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pap</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Determining the Target of Membrane Sterols on Voltage-Gated Potassium Channels</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Cel Biol. Lipids</source> <volume>1864</volume> (<issue>3</issue>), <fpage>312</fpage>&#x2013;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2018.12.006</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zakany</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Batta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>K&#xe1;rp&#xe1;ti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>M&#xe1;ndity</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>F&#xfc;l&#xf6;p</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>An &#x3c9;-3, but Not an &#x3c9;-6 Polyunsaturated Fatty Acid Decreases Membrane Dipole Potential and Stimulates Endo-Lysosomal Escape of Penetratin</article-title>. <source>Front. Cel Dev. Biol.</source> <volume>9</volume>, <fpage>647300</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.647300</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zidovetzki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Levitan</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Use of Cyclodextrins to Manipulate Plasma Membrane Cholesterol Content: Evidence, Misconceptions and Control Strategies</article-title>. <source>Biochim. Biophys. Acta (Bba) - Biomembranes</source> <volume>1768</volume> (<issue>6</issue>), <fpage>1311</fpage>&#x2013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2007.03.026</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>